Category:Heart failure policy

Back to Trailblazers Hub


How can heart failure advocates in Spain seize current opportunities to improve care?

Our latest policy brief attempts to answer this question, examining existing opportunities and mechanisms to advocate for guideline-recommended care in Spain.

Read More
Developments in international guidelines mark pivotal moment for the heart failure community

HFPN has launched ‘What’s new in international heart failure guidelines?’, a resource that summarises key changes in heart failure guidelines.

Read More
Register now for the Heart Failure Policy Summit 2022

Taking the form of four virtual sessions held in October and November, the 2022 Heart Failure Policy Summit will address how we can engage with policymakers and leaders to improve care for the millions of people living with heart failure across Europe.

Read More
Are we failing women with heart failure?

It has been argued that women are systematically discriminated against in healthcare, so what does this mean for women with heart failure?

Read More
HFPN calls for the improved management of worsening heart failure in a new report

The Heart Failure Policy Network has launched the ‘Spotlight on worsening heart failure’, which highlights the actions that decision-makers can take to prevent heart failure hospitalisations.

Read More
The future of heart failure care – key lessons learnt from the pandemic

After two years of disruption, many countries are lifting COVID-19 restrictions. We have been talking with the HFPN community about the key lessons learnt from the pandemic and how they can help shape the future of heart failure care.

Read More
The HFPN and 27 organisations demand urgent EU action on heart failure

The Heart Failure Policy Network has launched the Action Statement on Heart Failure, urging European institutions to address the growing burden of heart failure in the EU.

Read More
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .